For patients with advanced or metastatic RCC, fruquintinib plus sintilimab improves PFS compared to investigator’s choice of axilitinib or everolimus.

This article was originally published on Stateline. In a clear rebuke of recent federal health policy, 15 Democratic governors announced Wednesday they’ve formed a public health alliance that breaks ...

Regorafenib plus nivolumab did not improve survival over chemotherapy in patients with previously treated gastric/GEJ cancer.

Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data ...

In TNBC, pembrolizumab at a tenth of the current standard dose, plus chemotherapy, increased pCR compared to chemotherapy alone.

Adding abemaciclib to endocrine therapy improved overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer.

Prior authorization is placing a growing burden on radiation oncologists, leading to treatment delays and suboptimal treatment, and compromising patient safety, according to a survey presented at the ...

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...